Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Deciphera Pharmaceuticals LLC stock

Learn how to easily invest in Deciphera Pharmaceuticals LLC stock.

Deciphera Pharmaceuticals LLC is a drug manufacturers-specialty & generic business based in the US. Deciphera Pharmaceuticals LLC shares (DCPH) are listed on the NASDAQ and all prices are listed in US Dollars. Deciphera Pharmaceuticals LLC employs 280 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Deciphera Pharmaceuticals LLC

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – DCPH – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Deciphera Pharmaceuticals LLC stock price (NASDAQ: DCPH)

Use our graph to track the performance of DCPH stocks over time.

Deciphera Pharmaceuticals LLC shares at a glance

Information last updated 2022-06-25.
Latest market close$13.26
52-week range$6.51 - $38.91
50-day moving average $10.99
200-day moving average $14.42
Wall St. target price$10.78
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-4.90

Buy Deciphera Pharmaceuticals LLC shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
Finder Award
eToro
Stocks, ETFs, Cryptocurrency
$0
$10
$10
when you sign up and deposit $100
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, or TN.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.
SoFi Invest
Stocks, ETFs, Cryptocurrency
$0
$1
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0
$0
$125 - $625
when you open and fund an account with $25,000 - $250,000+
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Axos Bank Self Directed Investing
Stocks
$0
$1,000
$150
when you open an account and deposit at least $1500.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Deciphera Pharmaceuticals LLC stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Deciphera Pharmaceuticals LLC price performance over time

Historical closes compared with the close of $13.26 from 2022-07-01

1 week (2022-06-24) -3.42%
1 month (2022-06-02) 19.57%
3 months (2022-03-29) N/A
6 months (2021-12-31) 35.72%
1 year (2021-07-02) -63.62%
2 years (2020-07-02) -76.62%
3 years (2019-07-02) 23.09
5 years (2017-06-28) N/A

Deciphera Pharmaceuticals LLC financials

Revenue TTM $100.2 million
Gross profit TTM $-141,624,000
Return on assets TTM -33.05%
Return on equity TTM -73.73%
Profit margin -284.95%
Book value $4.63
Market capitalisation $909.2 million

TTM: trailing 12 months

Deciphera Pharmaceuticals LLC share dividends

We're not expecting Deciphera Pharmaceuticals LLC to pay a dividend over the next 12 months.

Deciphera Pharmaceuticals LLC share price volatility

Over the last 12 months, Deciphera Pharmaceuticals LLC's shares have ranged in value from as little as $6.51 up to $38.91. A popular way to gauge a stock's volatility is its "beta".

DCPH.US volatility(beta: 1.4)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Deciphera Pharmaceuticals LLC's is 1.3984. This would suggest that Deciphera Pharmaceuticals LLC's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Deciphera Pharmaceuticals LLC overview

Deciphera Pharmaceuticals, Inc. , a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts. .

Frequently asked questions

What percentage of Deciphera Pharmaceuticals LLC is owned by insiders or institutions?
Currently 27.902% of Deciphera Pharmaceuticals LLC shares are held by insiders and 69.225% by institutions.
How many people work for Deciphera Pharmaceuticals LLC?
Latest data suggests 280 work at Deciphera Pharmaceuticals LLC.
When does the fiscal year end for Deciphera Pharmaceuticals LLC?
Deciphera Pharmaceuticals LLC's fiscal year ends in December.
Where is Deciphera Pharmaceuticals LLC based?
Deciphera Pharmaceuticals LLC's address is: 200 Smith Street, Waltham, MA, United States, 02451
What is Deciphera Pharmaceuticals LLC's ISIN number?
Deciphera Pharmaceuticals LLC's international securities identification number is: US24344T1016
What is Deciphera Pharmaceuticals LLC's CUSIP number?
Deciphera Pharmaceuticals LLC's Committee on Uniform Securities Identification Procedures number is: 24344T101

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site